EX-99.2
TYME's Novel Metabolic-Based Cancer Therapy, SM-88,
FDA Grants Orphan Drug Designation for SM-88 for Treatment of Pancreatic Cancer
TYME Inc. - Our Science - SM-88 Overview
SM-88 Moves Forward in HopES Sarcoma Trial
Summary of randomized clinical trials in cardiovascular diseases with... | Download Table
Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer
TYME Technologies Inc - SM-88 Pancreatic Cancer Clinical Trial | Facebook
Patients With Metastatic Pancreatic Cancer Who Reported Higher Daily Step Counts Had Greater QoL on SM-88
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet
TYME Inc. - Our Science - SM-88 Overview
Pancreatic Cancer – between 2 to 3 times survival with SM-88 - TRIAL-IN Pharma
TYME's Novel Metabolic-Based Cancer Therapy, SM-88,
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer | SpringerLink
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 | Business Wire
TYME Inc. - Data Publications - Scientific Presentations
TYME To Make An Impact
Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 | Business Wire
A Trickster Enters the Fight Against Metastatic Cancers - Scientific American
TYME - Major Catalysts Ahead: 1) SM-88 Poster At ASCO 2021, 2) Results Of Strategic Review June 10. Game-Changing Oncology Platform (NASDAQ:TYME) | Seeking Alpha
Non-Hormonal Therapy for Recurrent Non-Metastatic Prostate Cancer
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor | Business
